Chapter 1. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. ALPHA-FETOPROTEIN (AFP) TESTING MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. ALPHA-FETOPROTEIN (AFP) TESTING MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– By Cancer Type

6.1. Stomach Cancer

6.2. Pancreatic Cancer

6.3. Testes Cancer

6.4. Liver Cancer

6.5. Biliary-Tract Cancer

Chapter 7. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– By  End-Use

7.1. Clinics

7.2. Hospitals

7.3. Others

Chapter 8. ALPHA-FETOPROTEIN (AFP) TESTING MARKET– By Region

8.1. North America

8.2. Europe

8.3.The Asia Pacific

8.4.Latin America

8.5. Middle-East and Africa

Chapter 9. ALPHA-FETOPROTEIN (AFP) TESTING MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Company 1

9.2. Company 2

9.3. Company 3

9.4. Company  4

9.5. Company 5

9.6. Company 6

9.7. Company 7

9.8. Company  8

9.9. Company 9

9.10. Company 10